NCT04049331View on ClinicalTrials.gov

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

January 30, 2027

Study Completion Date

January 30, 2027

Conditions
Hypogonadism, MaleFatigue Syndrome, Chronic
Interventions
DRUG

Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]

first two doses four weeks apart; following three more doses every ten weeks.

OTHER

placebo

first two doses four weeks apart; following three more doses every ten weeks.

Trial Locations (2)

98108

RECRUITING

Veterans Affairs Puget Sound Health Care System, Seattle

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Seattle Institute for Biomedical and Clinical Research

OTHER

NCT04049331 - Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | Biotech Hunter | Biotech Hunter